sugammadex

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Neuromuscular Blockade

Conditions

Neuromuscular Blockade

Trial Timeline

Sep 1, 2007 → Feb 1, 2008

NCT ID

NCT00535496

About sugammadex

sugammadex is a phase 3 stage product being developed by Merck for Neuromuscular Blockade. The current trial status is completed. This product is registered under clinical trial identifier NCT00535496. Target conditions include Neuromuscular Blockade.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05276804	Phase 3	Completed	Apr 13, 2022	Sep 3, 2024	Postoperative Urinary Retention
NCT03196167	Approved	Completed	May 13, 2017	Oct 10, 2020	Coronary Artery Bypass Graft and/or Aortic Valve Replacement Surgery
NCT02011490	Phase 1	Completed	Dec 11, 2013	Jun 6, 2014	Renal Insufficiency
NCT00826176	Phase 3	Completed	Jan 1, 2010	Aug 1, 2010	Anesthesia, General
NCT00702715	Phase 3	Completed	Sep 24, 2008	Mar 15, 2010	Anesthesia
NCT00535496	Phase 3	Completed	Sep 1, 2007	Feb 1, 2008	Neuromuscular Blockade
NCT00591786	Phase 2	Completed	Dec 5, 2005	Oct 19, 2006	Anesthesia, General
NCT00552929	Phase 2	Completed	Oct 4, 2005	Sep 15, 2006	Anesthesia, General
NCT00482599	Phase 3	Completed	Jun 1, 2005	Apr 13, 2006	Anesthesia, General

Competing Products

20 competing products in Neuromuscular Blockade

See all competitors

Product	Company	Stage	Hype Score
HRS-9190; under Inhalational Anesthesia + HRS-9190; under Intravenous Anesthesia + Cisatracurium (under Inhalational Anesthesia). + Cisatracurium (under Intravenous Anesthesia)	Jiangsu Hengrui Medicine	Phase 2	52
HRS-9190 + HRS-9190 + HRS-9190 + HRS-9190 + Rocuronium + Rocuronium	Jiangsu Hengrui Medicine	Phase 2	52
HRS-9190 + HRS-9190 + HRS-9190	Jiangsu Hengrui Medicine	Phase 2	52
Placebo + Sugammadex + Esmeron®	Merck	Phase 2	52
Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Sugammadex 16 mg/kg + Neostigmine + Glycopyrrolate + Rocuronium + Vecuronium	Merck	Approved	85
Deep neuromuscular block + Moderate neuromuscular block	Merck	Approved	85
Rocuronium + Succinylcholine + Cisatracurium + Mivacurium + Sugammadex + Neostigmine	Merck	Pre-clinical	23
Sugammadex + Rocuronium	Merck	Approved	85
sufficient dose of rocuronium + sugammadex 10 min after position change	Merck	Approved	85
neostigmine/glycopyrrolate + sugammadex	Merck	Approved	85
2 mg/kg sugammadex + 0.07 mg/kg neostigmine	Merck	Phase 3	77
Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Neostigmine + Glycopyrrolate + Neostigmine + Atropine	Merck	Approved	85
Rocuronium + Sugammadex + Cisatracurium + Neostigmine/Atropine + Succinylcholine	Merck	Approved	85
Sugammadex + Neostigmine	Merck	Approved	85
Sugammadex 2 mg/kg ABW + Sugammadex 2 mg/kg IBW + Sugammadex 4 mg/kg ABW + Sugammadex 4 mg/kg IBW + Neostigmine + Glycopyrrolate + Rocuronium or Vecuronium	Merck	Approved	85
sugammadex + Neostigmine + Glycopyrrolate	Merck	Approved	85
Group A. "Muscle relaxant #1": rocuronium + sugammadex; "Muscle relaxant #2": succinylcholine +saline + Group B. "Muscle relaxant #2": succinylcholine +saline; "Muscle relaxant #1": rocuronium + sugammadex;	Merck	Phase 2	52
Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Neostigmine + Glycopyrrolate + Neostigmine + Atropine	Merck	Approved	85
Rocuronium Bromide + Rocuronium Bromide	Merck	Approved	85
Rocuronium (moderate NMB) + Rocuronium (deep NMB)	Merck	Pre-clinical	23

Other Products from Merck

DuleraApproved

ImipenemApproved

Mavenclad®Approved

raltegravir + PlaceboApproved

alendronate sodiumApproved